Tata Nifty MidSmall Healthcare Index Fund Direct Growth
EquityIndex FundsVery High Risk
Direct
NAV (21-Feb-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹126 Cr
Expense Ratio
0.47%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
About this fund
As of 21-Feb-25, it has a Net Asset Value (NAV) of ₹11.23, Assets Under Management (AUM) of 126.29 Crores, and an expense ratio of 0.47%.
- Tata Nifty MidSmall Healthcare Index Fund Direct Growth has given a CAGR return of 12.26% since inception.
- The fund's asset allocation comprises around 100.20% in equities, 0.00% in debts, and -0.20% in cash & cash equivalents.
- You can start investing in Tata Nifty MidSmall Healthcare Index Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+12.26%
— (Cat Avg.)
Portfolio Summaryas of 31st January 2025
| Equity | ₹126.55 Cr | 100.20% |
| Others | ₹-0.25 Cr | -0.20% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹18.79 Cr | 14.87% |
| Lupin Ltd | Equity | ₹11.96 Cr | 9.47% |
| Fortis Healthcare Ltd | Equity | ₹7.95 Cr | 6.29% |
| Aurobindo Pharma Ltd | Equity | ₹7.81 Cr | 6.18% |
| Alkem Laboratories Ltd | Equity | ₹6.41 Cr | 5.08% |
| Mankind Pharma Ltd | Equity | ₹6.03 Cr | 4.78% |
| Laurus Labs Ltd | Equity | ₹5.48 Cr | 4.34% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹5.22 Cr | 4.13% |
| Ipca Laboratories Ltd | Equity | ₹4.67 Cr | 3.70% |
| Biocon Ltd | Equity | ₹3.89 Cr | 3.08% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹3.56 Cr | 2.82% |
| Piramal Pharma Ltd | Equity | ₹3.42 Cr | 2.71% |
| Abbott India Ltd | Equity | ₹3.25 Cr | 2.57% |
| Syngene International Ltd | Equity | ₹3.22 Cr | 2.55% |
| Suven Pharmaceuticals Ltd | Equity | ₹3.19 Cr | 2.53% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.01 Cr | 2.38% |
| Gland Pharma Ltd | Equity | ₹2.89 Cr | 2.29% |
| Ajanta Pharma Ltd | Equity | ₹2.7 Cr | 2.14% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.57 Cr | 2.03% |
| Dr. Lal PathLabs Ltd | Equity | ₹2.54 Cr | 2.01% |
| Natco Pharma Ltd | Equity | ₹2.5 Cr | 1.98% |
| Narayana Hrudayalaya Ltd | Equity | ₹2.24 Cr | 1.78% |
| Poly Medicure Ltd | Equity | ₹2.11 Cr | 1.67% |
| Global Health Ltd | Equity | ₹2.06 Cr | 1.63% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.95 Cr | 1.54% |
| Granules India Ltd | Equity | ₹1.92 Cr | 1.52% |
| Rainbow Childrens Medicare Ltd | Equity | ₹1.69 Cr | 1.34% |
| Alembic Pharmaceuticals Ltd | Equity | ₹1.23 Cr | 0.97% |
| Sanofi India Ltd | Equity | ₹1.2 Cr | 0.95% |
| Metropolis Healthcare Ltd | Equity | ₹1.11 Cr | 0.88% |
| Net Current Liabilities | Cash | ₹-0.37 Cr | 0.30% |
| A) Repo | Cash - Repurchase Agreement | ₹0.12 Cr | 0.10% |
Allocation By Market Cap (Equity)
Large Cap Stocks
--
Mid Cap Stocks
66.38%
Small Cap Stocks
33.82%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹126.55 Cr | 100.20% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Kapil Menon
Since April 2024
Rakesh Prajapati
Since December 2024
Additional Scheme Detailsas of 31st January 2025
ISIN INF277KA1BG3 | Expense Ratio 0.47% | Exit Load No Charges | Fund Size ₹126 Cr | Age 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹613.55 Cr | 4.2% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹613.55 Cr | 3.6% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹466.86 Cr | -5.5% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹716.78 Cr | 3.7% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1945.75 Cr | 2.5% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹1208.99 Cr | -2.2% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹716.78 Cr | 4.2% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹466.86 Cr | -5.0% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1945.75 Cr | 3.1% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1208.99 Cr | -2.7% |
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
What is the portfolio composition of Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
Who manages the Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
- Kapil Menon
- Rakesh Prajapati
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Tata Nifty MidSmall Healthcare Index Fund Direct Growth
EquityIndex FundsVery High Risk
Direct
NAV (21-Feb-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹126 Cr
Expense Ratio
0.47%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 21-Feb-25, it has a Net Asset Value (NAV) of ₹11.23, Assets Under Management (AUM) of 126.29 Crores, and an expense ratio of 0.47%.
- Tata Nifty MidSmall Healthcare Index Fund Direct Growth has given a CAGR return of 12.26% since inception.
- The fund's asset allocation comprises around 100.20% in equities, 0.00% in debts, and -0.20% in cash & cash equivalents.
- You can start investing in Tata Nifty MidSmall Healthcare Index Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+12.26%
— (Cat Avg.)
Portfolio Summaryas of 31st January 2025
| Equity | ₹126.55 Cr | 100.20% |
| Others | ₹-0.25 Cr | -0.20% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹18.79 Cr | 14.87% |
| Lupin Ltd | Equity | ₹11.96 Cr | 9.47% |
| Fortis Healthcare Ltd | Equity | ₹7.95 Cr | 6.29% |
| Aurobindo Pharma Ltd | Equity | ₹7.81 Cr | 6.18% |
| Alkem Laboratories Ltd | Equity | ₹6.41 Cr | 5.08% |
| Mankind Pharma Ltd | Equity | ₹6.03 Cr | 4.78% |
| Laurus Labs Ltd | Equity | ₹5.48 Cr | 4.34% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹5.22 Cr | 4.13% |
| Ipca Laboratories Ltd | Equity | ₹4.67 Cr | 3.70% |
| Biocon Ltd | Equity | ₹3.89 Cr | 3.08% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹3.56 Cr | 2.82% |
| Piramal Pharma Ltd | Equity | ₹3.42 Cr | 2.71% |
| Abbott India Ltd | Equity | ₹3.25 Cr | 2.57% |
| Syngene International Ltd | Equity | ₹3.22 Cr | 2.55% |
| Suven Pharmaceuticals Ltd | Equity | ₹3.19 Cr | 2.53% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.01 Cr | 2.38% |
| Gland Pharma Ltd | Equity | ₹2.89 Cr | 2.29% |
| Ajanta Pharma Ltd | Equity | ₹2.7 Cr | 2.14% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.57 Cr | 2.03% |
| Dr. Lal PathLabs Ltd | Equity | ₹2.54 Cr | 2.01% |
| Natco Pharma Ltd | Equity | ₹2.5 Cr | 1.98% |
| Narayana Hrudayalaya Ltd | Equity | ₹2.24 Cr | 1.78% |
| Poly Medicure Ltd | Equity | ₹2.11 Cr | 1.67% |
| Global Health Ltd | Equity | ₹2.06 Cr | 1.63% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.95 Cr | 1.54% |
| Granules India Ltd | Equity | ₹1.92 Cr | 1.52% |
| Rainbow Childrens Medicare Ltd | Equity | ₹1.69 Cr | 1.34% |
| Alembic Pharmaceuticals Ltd | Equity | ₹1.23 Cr | 0.97% |
| Sanofi India Ltd | Equity | ₹1.2 Cr | 0.95% |
| Metropolis Healthcare Ltd | Equity | ₹1.11 Cr | 0.88% |
| Net Current Liabilities | Cash | ₹-0.37 Cr | 0.30% |
| A) Repo | Cash - Repurchase Agreement | ₹0.12 Cr | 0.10% |
Allocation By Market Cap (Equity)
Large Cap Stocks
--
Mid Cap Stocks
66.38%
Small Cap Stocks
33.82%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹126.55 Cr | 100.20% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Kapil Menon
Since April 2024
Rakesh Prajapati
Since December 2024
Additional Scheme Detailsas of 31st January 2025
ISIN INF277KA1BG3 | Expense Ratio 0.47% | Exit Load No Charges | Fund Size ₹126 Cr | Age 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty MidSmall Healthcare Index (TRI) |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹613.55 Cr | 4.2% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹613.55 Cr | 3.6% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹466.86 Cr | -5.5% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹716.78 Cr | 3.7% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1945.75 Cr | 2.5% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹1208.99 Cr | -2.2% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹716.78 Cr | 4.2% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹466.86 Cr | -5.0% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1945.75 Cr | 3.1% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1208.99 Cr | -2.7% |
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
What is the portfolio composition of Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
Who manages the Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
- Kapil Menon
- Rakesh Prajapati
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
